Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiaan Engelborghs

Showing results (91-100 of 374) with videos related to

Pageof 38
Sort By:
Epilepsia|July 1, 2022
Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's diseaseMaxime Vande Vyver, Melissa Barker-Haliski, Najat Aourz, et al.
Journal of Alzheimer'S Disease : JAD|February 3, 2016
Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's DiseaseEllis Niemantsverdriet, Joery Goossens, Hanne Struyfs, et al.
Neurobiology of Aging|April 24, 2021
Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's diseaseJulie Hoogmartens, Elisabeth Hens, Sebastiaan Engelborghs, et al.
Neurobiology of Aging|June 6, 2021
Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patientsLiene Bossaerts, Elisabeth Hens, Bernard Hanseeuw, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 25, 2014
The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization InitiativeJosé Luis Molinuevo, Kaj Blennow, Bruno Dubois, et al.
Journal of Alzheimer'S Disease : JAD|May 14, 2013
Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levelsSylvie Slaets, Nathalie Le Bastard, Jean-Jacques Martin, et al.
Journal of Alzheimer'S Disease : JAD|October 5, 2012
Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's diseaseNathalie Le Bastard, Laetitia Aerts, Kristel Sleegers, et al.
Human Mutation|May 23, 2009
APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer diseaseKarolien Bettens, Nathalie Brouwers, Sebastiaan Engelborghs, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 16, 2022
Associations of Bilateral Vestibulopathy With Cognition in Older Adults Matched With Healthy Controls for Hearing StatusJoyce Bosmans, Hanne Gommeren, Griet Mertens, et al.
International Journal of Geriatric Psychiatry|October 20, 2010
Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categoriesMarcel J H Aries, Nathalie Le Bastard, Hans Debruyne, et al.
Pageof 38

Showing results (91-100 of 374) with videos related to

Sort By:
Pageof 38
Epilepsia|July 1, 2022
Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's diseaseMaxime Vande Vyver, Melissa Barker-Haliski, Najat Aourz, et al.
Journal of Alzheimer'S Disease : JAD|February 3, 2016
Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's DiseaseEllis Niemantsverdriet, Joery Goossens, Hanne Struyfs, et al.
Neurobiology of Aging|April 24, 2021
Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's diseaseJulie Hoogmartens, Elisabeth Hens, Sebastiaan Engelborghs, et al.
Neurobiology of Aging|June 6, 2021
Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patientsLiene Bossaerts, Elisabeth Hens, Bernard Hanseeuw, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 25, 2014
The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization InitiativeJosé Luis Molinuevo, Kaj Blennow, Bruno Dubois, et al.
Journal of Alzheimer'S Disease : JAD|May 14, 2013
Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levelsSylvie Slaets, Nathalie Le Bastard, Jean-Jacques Martin, et al.
Journal of Alzheimer'S Disease : JAD|October 5, 2012
Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's diseaseNathalie Le Bastard, Laetitia Aerts, Kristel Sleegers, et al.
Human Mutation|May 23, 2009
APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer diseaseKarolien Bettens, Nathalie Brouwers, Sebastiaan Engelborghs, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 16, 2022
Associations of Bilateral Vestibulopathy With Cognition in Older Adults Matched With Healthy Controls for Hearing StatusJoyce Bosmans, Hanne Gommeren, Griet Mertens, et al.
International Journal of Geriatric Psychiatry|October 20, 2010
Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categoriesMarcel J H Aries, Nathalie Le Bastard, Hans Debruyne, et al.
Pageof 38